Estrella Immunopharma, Inc.
ESLA · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | -0.23 | 1.44 | -0.03 |
| FCF Yield | -17.36% | -41.50% | -1.76% | -2.47% |
| EV / EBITDA | -4.87 | -4.73 | -86.99 | -4,875.33 |
| Quality | ||||
| ROIC | -6,154.51% | -171.06% | -16.68% | -2.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 2.20 | 1.05 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 52.46% | -1,439.33% | 27.61% | -114.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.57 | -0.67 | 366.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |